NEW YORK (GenomeWeb News) – Nine months after saying that they would form a new molecular diagnostics joint venture, called Dx Assays, in Singapore, Qiagen and Bio*One Capital said today that the new venture has officially launched its operations.
The partners announced last December that they would launch the venture, which will focus on developing tests for infectious diseases and oncology applications. It expects to complete initial assay projects by the end of this year and to launch its first products over the next one to two years.
“By leveraging the development capabilities of Dx Assays, Qiagen can further strengthen its presence in the rapidly growing Asian market and expand its global portfolio of molecular testing solutions,” said Qiagen CEO Peer Schatz in a statement.
He noted that Asia is the firm’s fastest-growing market, and the company has seven offices in the region with more than 370 employees.
Earlier this year, Qiagen opened a new service solutions center in Singapore to serve the entire Asia-Pacific region. Qiagen said that the new center will help it serve customers in the research, applied testing, pharmaceutical, and molecular diagnostics markets in the entire Asia-Pacific region including Australia.